 |
(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid |
|---|---|
| Trade Name | |
| Orphan Indication | Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy |
| USA Market Approval | USA |
| USA Designation Date | 2003-03-31 00:00:00 |
| Sponsor | Intarcia Therapeutics, Inc.;24650 Industrial Blvd;Hayward, California, 94545 |
